Approved for To treat patients with neovascular (wet) age-related macular degeneration. 12.1 Mechanism of Action Bevacizumab is a human vascular endothelial growth factor (VEGF) inhibitor. Bevacizumab binds VEGF and prevents the interaction of VEGF to its receptors (Flt-1 and KDR) on… Side effects, costs, interactions, manufacturer, and generic alternatives sourced from FDA labels, openFDA…
Loading full data from Know Your Drugs Institute…